Marco Alessandrini

Marco Alessandrini currently serves as the Head of Early Stage Ventures in Cell and Gene Therapy at Remora Biotech, a position held since May 2025. Prior experience includes roles as Chief Technology Officer and Chief Executive Officer at Antion Biosciences SA from November 2020 to May 2025, and as a Senior Scientist at Université de Genève, focusing on translational research from July 2016 to September 2020. Early career involvement includes consulting and post-doctoral work at the Institute for Cellular and Molecular Medicine, University of Pretoria, from January 2011 to June 2016, and managing the Clinical Trials Division at Key Oncologics from September 2008 to December 2010. Educational qualifications consist of a PhD in Biochemistry and Molecular Biology from North-West University and an MSc in Biochemistry from Potchefstroom University for CHE.